This site is intended for health professionals only
Thursday 15 November 2018
Share |

Topic: Latest News

November 9, 2018

NHS England spends over £1bn per year on diabetes prescriptions, data has revealed.
 

November 8, 2018
Vyxeos is an advanced liposomal formulation that delivers a synergistic molar ratio of daunorubicin and cytarabine

Jazz Pharmaceuticals plc has announced that the National Institute for Health and Care Excellence (NICE) has published a Final Appraisal Determination (FAD) recommending Vyxeos® 44 mg/100 mg powder for concentrate for solution for infusion for routine use on the National Health Service (NHS) in England and Wales.

Vyxeos is recommended for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC)1 – two types of secondary AML.

November 7, 2018

An ovarian cancer drug could be an effective treatment for a difficult-to-treat type of brain tumour, research by a cancer charity has revealed.
 
Olaparib could leak through the blood brain barrier to treat glioblastoma – a condition which many other drugs have failed to treat – according to a study presented at the National Cancer Research Institute’s (NCRI) Cancer Conference in Liverpool on Monday (5 November).
 

November 5, 2018

The ubiquity of the pink ribbon campaign, the prevalence of precision medicine as a recurring theme in every scientific and medical journal, and the very fact that BRCA has entered the lexicon of society – globally – suggests that breast cancer testing is standard. Indeed, something that has been part of everyday life for some time.
 

November 5, 2018

New legislation making it easier to access medical cannabis will only benefit a few patients, NHS England has said.
 

November 2, 2018
There should be vegetarian and vegan alternatives to medicines such as vaccines, a charity has said.

There should be vegetarian and vegan alternatives to medicines such as vaccines, a charity has said.
 
The Vegetarian Society said that vegetarian and vegan version of medicines and flu vaccines should be made available to patients to ensure "everyone has the best chance of staying healthy and feeling good about it".
 
Different flu vaccines contain various animal product derivatives, from being grown on eggs to the inclusion of porcine gelatine as an ingredient.
 

October 31, 2018

Scientists have discovered the mechanism by which a bacterium adheres to human cells, which is essential for the onset of bacterial infection and disease development.
 
The researchers from the Molecular Biology Institute of Barcelona (IBMB) and the Institute of Biotechnology and Biomedicine (IBB) studied the bacterium mycoplasma genitalium (Mgen) and how it adheres to human cells.
 
They found the mechanism by which it interacts with cells, which the researchers hope will lead to new treatments to fight the infection.
 

October 31, 2018

Researchers have discovered a way of re-sensitising tumour cells that are resistant to cancer drugs.
 
The study, conducted by biologists at the University of California in San Diego, found that a human gene known as Schlafen 11 controls the sensitivity of tumour cells to DNA-damaging agents, which make up most of the widely used cancer drugs.
 

October 29, 2018
Medicines watchdog seizes over £2m counterfeit medicines in UK drugs bust

More than £2m worth of falsified medicines have been seized in the UK in less than three weeks, the Government’s medicines watchdog has revealed.
 
The Medicines and Healthcare products Regulatory Agency (MHRA) said on Wednesday (24 October) that it intercepted one million doses of counterfeit medicines worth over £2m between 9 and 27 October including diazepam, modafinil and dermal fillers.
 

October 26, 2018

The number of patients diagnosed with bowel cancer in Europe has been steadily increasing over the past 25 years, according to new research.
 
Between 2008 and 2016, diagnosis rates for bowel cancer, which is also known as colorectal cancer, increased by 6% every year in adults aged 20 to 39 years old.
 
For colon cancer, rates increased by 1.5% a year between 1990 and 2008, and an even greater 7.4% annually between 2008 and 2016, whereas rectal cancer was slightly slower at 1.8% per year from 1990 to 2016.
 

October 26, 2018

Cannabis oil significantly improves symptoms of Crohn’s disease despite having no effect on gut inflammation, according to new research.
 
The study, revealed at UEG Week conference in Vienna this week, found that cannabis produced clinical remission in up to 65% of individuals after eight weeks of treatment. However, it also found that it did this despite having no effect on gut inflammation, contrary to previous medical thinking.
 

October 25, 2018

The European Commission has granted Kigabeq paediatric use marketing authorisation (PUMA) following the recommendation of the Committee for Medicinal Products for Human Use (CHMP).
 
Kigabeq is meant for the treatment of infantile spasms, or West’s syndrome, which is an uncommon and severe form of epilepsy associated with a highly-resistant seizure type and a rapid psychomotor regression. It can also be used to treat partial epilepsy in infants and children from one month to seven years of age.
 

October 25, 2018

Stockpiling six weeks worth of medicines after a no-deal Brexit could take over a year due to creating extra storage for drugs that need to be kept in certain conditions, a Government committee has heard.
 

October 25, 2018
New study data also confirm efficacy for Stelara (ustekinumab) in Crohn's disease patients who are naïve and refractory/intolerant to tumour necrosis factor antagonist treatment

Janssen has announced new three-year data from the IM-UNITI study, which demonstrates the continued efficacy of ustekinumab in improving clinical remission rates and shows ustekinumab to be generally well-tolerated in patients with Crohn’s disease.1

The data from the IM-UNITI trial, which will continue for a further two years, were presented today at the 26th United European Gastroenterology Week (UEGW) congress in Austria, Vienna.

October 24, 2018

An implanted cardiac defibrillator (ICD) can effectively put a stop to any underlying cardiac arrhythmia, a study has found [24 October 2018].
 
In a long-term observational study involving 1,500 patients, researchers from MedUni Vienna's Department of Medicine II (division of cardiology) have shown that the programming selected for the implanted defibrillators (ICDs) plays a major role.
 
It was found that the most "defensive" possible procedure was safe and, at the same time, significantly reduced inappropriate therapy.

October 24, 2018

Global biotechnology company Amgen’s Repatha® (evolocumab) has been selected as a Rapid Uptake Product by the Accelerated Access Collaborative (AAC), the Department of Health and Social Care (DHSC) has announced [October 23 2018].
 

October 17, 2018

ImraldiTM is approved in the European Union (EU) for 13 of the same complex autoimmune conditions as its reference product and is now available in the UK via the NHS.

Imraldi is approved in Europe for the treatment of rheumatoid arthritis (RA), juvenile idiopathic arthritis (polyarticular juvenile idiopathic arthritis; enthesitis-related arthritis), axial spondyloarthritis (ankylosing spondylitis (AS) and axial spondyloarthritis with radiographic evidence of AS).

October 17, 2018

The Child health in 2030 in England: comparisons with other wealthy countries report, published [15 October] by the Royal College of Paediatrics and Child Health (RCPCH), compared England with European and other western countries known as the EU15+.
 
Researchers used long-term historical data to project outcomes for children and young people’s health in 2030.
 

October 17, 2018

Eli Lilly and Company announced today that the European Commission has granted marketing authorisation (MA) for Verzenios® (abemaciclib) for the treatment of women with hormone receptor-positive (HR+), epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer, in combination with an aromatase inhibitor (AI) or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.1
 

October 17, 2018

Pharmacists must implement new validation processes from today (17 October) to prioritise the limited stocks of EpiPen junior 150 microgram (mcg), the Department of Health and Social Care (DHSC) and NHS England have said.

Following ‘critical’ shortages of the device, the DHSC and NHS England asked pharmacists to validate both private and NHS prescriptions before ordering and supplying the device to a patient.

October 17, 2018

Pregabalin and gabapentin will be reclassified as class C drugs next year following a rising numbers of deaths linked to the drugs, the UK Government has said.
 

October 12, 2018

Lab solutions company Roche Diagnostics has launched a new business unit called Roche Healthcare Consulting. 
 
The new unit will focus on digital diagnostics and help laboratories, hospitals and other healthcare providers to “optimise their performance”.
 
The global consulting service will feature over 250 experienced consultants who specialise in business, healthcare and technology, and will use data analytics and reports to help clients improve their operational, clinical and financial performance.
 

October 11, 2018

A one-off DNA test could spot people at risk of a heart attack in adulthood much earlier in life for just £40, according to new research.
 
The study, part-funded by the charity the British Heart Foundation and published in the Journal of the American College of Cardiology, developed a new scoring system to identify those at risk because of their genetics.
 
It costs £40, making it a “cost effective” way of helping preventing heart disease according to the report’s authors.
 

October 9, 2018

Women with urinary incontinence should only be offered mesh surgery as a last resort, according to new draft guidelines.
 
The full range of non-surgical options should be offered to women who have urinary incontinence and pelvic organ prolapse before any operations, said the National Institute for Health and Care Excellence (NICE).
 
For urinary incontinence, lifestyle interventions, physical therapies, behavioural therapies and medicines should be considered before surgery.